Core Insights - The Rostock International Parkinson's Disease (ROPAD) Study reveals that approximately 90% of genetically confirmed Parkinson's disease patients have variants in the LRRK2 or GBA1 genes, indicating potential candidates for gene-targeted trials [1] - The study shows that around 15% of Parkinson's disease cases are linked to genetic variants, primarily LRRK2 and GBA1, emphasizing the importance of genetic testing in patient care [1] - CENTOGENE has launched the ROPAD Consortium to enhance PD research and treatment through collaboration with neurologists and non-profit organizations [2] Company Overview - CENTOGENE is focused on providing data-driven solutions for rare and neurodegenerative diseases, utilizing multiomic technologies and the CENTOGENE Biodatabank for precision medicine [4][6] - The company has built a network of approximately 30,000 active physicians and has conducted genetic testing on over 18,000 participants in the ROPAD Study over five years [5][3] - CENTOGENE's Biodatabank includes data from over 850,000 patients across 120 countries, contributing to more than 300 peer-reviewed publications [6][7] Research and Development - The ROPAD Study aims to characterize the genetics of Parkinson's disease to improve understanding of its etiology, diagnosis, and severity [3] - The study involved genetic testing of 50 genes in over 12,500 patients, with significant findings related to LRRK2, GBA1, PRKN, SNCA, and PINK1 genes [1] - The integration of genetic testing in routine care is expected to facilitate access to treatments and accelerate the development of gene-specific therapies [1]
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors